Treatment to suppression of focal lesions on positron

  • Slides: 8
Download presentation
Treatment to suppression of focal lesions on positron emission tomography-computed tomography is a therapeutic

Treatment to suppression of focal lesions on positron emission tomography-computed tomography is a therapeutic goal in newly diagnosed multiple myeloma by Faith E. Davies, Adam Rosenthal, Leo Rasche, Nathan M. Petty, James E. Mc. Donald, James A. Ntambi, Doug M. Steward, Susan B. Panozzo, Frits van Rhee, Maurizio Zangari, Carolina D. Schinke, Sharmilan Thanendrarajan, Brian Walker, Niels Weinhold, Bart Barlogie, Antje Hoering, and Gareth J. Morgan haematol Volume 103(6): 1047 -1053 June 3, 2018 © 2018 by Ferrata Storti Foundation

Positron emission tomography with computed tomography sample availability of cases entered into the TT

Positron emission tomography with computed tomography sample availability of cases entered into the TT 4 -6 studies at the different timepoints of assessment. Faith E. Davies et al. Haematologica 2018; 103: 1047 -1053 © 2018 by Ferrata Storti Foundation

Patients’ characteristics, overall and by protocol. Faith E. Davies et al. Haematologica 2018; 103:

Patients’ characteristics, overall and by protocol. Faith E. Davies et al. Haematologica 2018; 103: 1047 -1053 © 2018 by Ferrata Storti Foundation

Survival data according to number of focal lesions (FLs). Faith E. Davies et al.

Survival data according to number of focal lesions (FLs). Faith E. Davies et al. Haematologica 2018; 103: 1047 -1053 © 2018 by Ferrata Storti Foundation

Progression-free and overall survival estimates at each positron emission tomography with computed tomography time

Progression-free and overall survival estimates at each positron emission tomography with computed tomography time point according to the number of focal lesions. Faith E. Davies et al. Haematologica 2018; 103: 1047 -1053 © 2018 by Ferrata Storti Foundation

P-value for progression-free and overall survival estimates for patients with and without lesions at

P-value for progression-free and overall survival estimates for patients with and without lesions at each positron emission tomography with computed tomography time point. Faith E. Davies et al. Haematologica 2018; 103: 1047 -1053 © 2018 by Ferrata Storti Foundation

Paired day 1, 7, and end of induction positron emission tomography with computed tomography

Paired day 1, 7, and end of induction positron emission tomography with computed tomography (PET-CT). Faith E. Davies et al. Haematologica 2018; 103: 1047 -1053 © 2018 by Ferrata Storti Foundation

Multivariate analyses of progression-free and overall survival. Faith E. Davies et al. Haematologica 2018;

Multivariate analyses of progression-free and overall survival. Faith E. Davies et al. Haematologica 2018; 103: 1047 -1053 © 2018 by Ferrata Storti Foundation

Tumefactive demyelinating lesions TDLs Tumefactive demyelinating lesions 1979VanTumefactive demyelinating lesions TDLs Tumefactive demyelinating lesions 1979Van
Primary lesions are denovo lesions while secondary arePrimary lesions are denovo lesions while secondary are
Skin lesions The Primary Lesions Macule Papule NoduleSkin lesions The Primary Lesions Macule Papule Nodule
DOPPLER IN REGURGITANT LESIONS Regurg Lesions Doppler IndirectDOPPLER IN REGURGITANT LESIONS Regurg Lesions Doppler Indirect
ORAL PATHOLOGY Outline White lesions Red lesions UlcerativeORAL PATHOLOGY Outline White lesions Red lesions Ulcerative
Vulval Vaginal lesions VIP Vulval Vaginal lesions DRVulval Vaginal lesions VIP Vulval Vaginal lesions DR
n PLEURAL LESIONS Inflammatory Pleural Lesions MESOTHELIOMA nn PLEURAL LESIONS Inflammatory Pleural Lesions MESOTHELIOMA n